The FDA on May 20, 2022, approved VIDAZA® for pediatric patients with newly diagnosed Juvenile MyeloMonocytic Leukemia (JMML). VIDAZA® is a product of Celgene Corp.
Other Pages – Bottom Ad
Advertisement
Subscribe
Other Pages – Top Ad
Advertisement